Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Drug Development A Priority For US FDA’s New Oncology Center Of Excellence

Executive Summary

Existing regulatory authorities could be optimized to speed development of promising pediatric cancer therapeutics, particularly those that don’t work in adult cancers.


Related Content

Pediatric Study Timelines Could Change Under Senate PDUFA Bill
Will Patient-Reported Data Require New Drug Labeling Framework?
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Trump Promises Changes To 'A Lot Of Rules' At US FDA
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
The Evolution Of 21st Century Cures Legislation
FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence
Pediatric Study Requirements For Cancer Have FDA Support, But Pose Industry Challenges
FDA's Pazdur Jumps Over To New 'Moonshot' Role
Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, FDA Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts